Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1368)	5/28/2001 3:49:13 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1477

Scios Inc short interest increased to 2,245,411 on May 15, from 778,750 in April, an increase of 188.3% which earned it 8th place on the largest % gain in short interest for May. I'd sure hate to be the hedge fund manager(s) with the short positions come Tuesday morning..:-) Ian. interactive.wsj.com

To: Miljenko Zuanic who wrote (1368)	5/28/2001 5:50:53 PM
From: Robert Cohen	Read Replies (2) \| Respond to of 1477

To suggest that I or any Emergency Physician would choose a therapeutic agent based on some economic benefit to either the physician or to the hospital is absurd. For example, in the treatment of acute myocardial infarction (heart attack)the decision to use thrombolytic therapy is based ONLY on the indications for its use not on the ability of the patient to pay or the type of insurance coverage. In my 20+ years of practice I have never been approached by hospital administrators or another physician to alter my treatment based on economic issues. NTG is in fact safe and effective and cheap. Whether Scios's new drug will become the standard of care in the treatment of pulmonary edema will not only depend on the results of the double blind study but also how well it is marketed. Finally, all of the press releases indicate that IV NTG is the standard of care. I repeat that I rarely am forced to use IV NTG in this setting. Robert